Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Marc Bonaca and Judith Hsia.

 
Connection Strength
  
 
 
9.324
  
  1. Hsia J, Shivappa N, Bakhai A, Bover J, Butler J, Ferraro PM, Fried L, Schneider MP, Tangri N, Winkelmayer WC, Bishop M, Chen H, Sundin AK, Bonaca MP. Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making. Clin Kidney J. 2024 Oct; 17(10):sfae295.
    View in: PubMed
    Score: 0.950
  2. Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, Barnathan ES, Bonaca MP. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thromb Haemost. 2024 Jul; 124(7):649-655.
    View in: PubMed
    Score: 0.895
  3. Hsia J, Guthrie NL, Lupinacci P, Gubbi A, Denham D, Berman MA, Bonaca MP. Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes. Diabetes Care. 2022 12 01; 45(12):2976-2981.
    View in: PubMed
    Score: 0.837
  4. Hsia J, Szarek M, Anand S, Patel MR, Debus S, Berkowitz SD, Muehlhofer E, Haskell LP, Bauersachs RM, Bonaca MP. Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. J Am Coll Cardiol. 2021 08 17; 78(7):757-759.
    View in: PubMed
    Score: 0.765
  5. Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021 12; 26(6):608-612.
    View in: PubMed
    Score: 0.754
  6. Canonico ME, Hess CN, Naveh S, Rogers RK, Nehler MR, Hogan SE, Hsia JA, Berkowitz SD, Bonaca MP. Prescription of aspirin plus low-dose rivaroxaban in patients with peripheral artery disease after lower-extremity revascularization. Vasc Med. 2025 Apr 30; 1358863X251331561.
    View in: PubMed
    Score: 0.247
  7. Hess CN, Daffron A, Nehler MR, Szarek M, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Early combination lipid-lowering therapy is associated with greater achievement of goal LDL-C: Insights from the OPTIMIZE PAD-1 trial. Vasc Med. 2025 Jan 27; 1358863X241309839.
    View in: PubMed
    Score: 0.243
  8. Bonaca MP, Lang NN, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, Strnadova C, Klaar S, Dent S, Janicijevic TK, Herrmann J, Barac A, de Boer RA, Deswal A, Schou M, Neilan TG, van der Meer P, Moslehi J, Kondapalli L, Ky B, Fernandez TL, Cornell RF, Flaig TW, Hsia J, Sharon E, de Azambuja E, Seltzer J, Januzzi JL, Petrie MC. Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer. JACC CardioOncol. 2025 Feb; 7(2):83-95.
    View in: PubMed
    Score: 0.241
  9. Naveh S, Rogers RK, Hess CN, Nehler MR, Hsia J, Bonaca MP. Multidisciplinary Management of Chronic?Limb Threatening Ischemia. JACC Case Rep. 2024 Dec 04; 29(23):102717.
    View in: PubMed
    Score: 0.240
  10. Gluckman TJ, Chiu ST, Rider D, Tseng PK, Mudd JO, Remick JD, Granowitz C, Carroll A, Sikirica S, Canonico ME, Hsia J, Bonaca MP. Relationship Between Left Ventricular Ejection Fraction and ICD-10 Codes Among Patients Hospitalized With Heart Failure. Clin Cardiol. 2024 12; 47(12):e70055.
    View in: PubMed
    Score: 0.240
  11. Canonico ME, Low Wang CC, Hsia J, Debus ES, Nehler MR, Patel MR, Anand SS, Ycas J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs R, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in?Fragile Patients After Lower Extremity?Revascularization. J Am Coll Cardiol. 2024 Aug 27; 84(9):801-811.
    View in: PubMed
    Score: 0.236
  12. Hess CN, Daffron A, Nehler MR, Morrison JT, Buchanan CE, Szarek M, Anderson VE, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024 Jun 25; 83(25):2658-2670.
    View in: PubMed
    Score: 0.233
  13. Morrison JT, Canonico ME, Anand SS, Patel MR, Debus ES, Nehler MR, Hess CN, Hsia J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation. 2024 May 07; 149(19):1536-1539.
    View in: PubMed
    Score: 0.231
  14. Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH, Johri S, Pursley MS, Gupta R, Meehan PS, Franchi F, Effron MB, Marshall D, Graybill CA, Huebler SP, Keuer T, Bristow MR, Bonaca MP. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arterioscler Thromb Vasc Biol. 2023 08; 43(8):1572-1582.
    View in: PubMed
    Score: 0.218
  15. Canonico ME, Piccolo R, Avvedimento M, Leone A, Esposito S, Franzone A, Giugliano G, Gargiulo G, Hess CN, Berkowitz SD, Hsia J, Cirillo P, Esposito G, Bonaca MP. Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J Cardiovasc Dev Dis. 2023 Apr 10; 10(4).
    View in: PubMed
    Score: 0.214
  16. Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med. 2023 06; 28(3):233-235.
    View in: PubMed
    Score: 0.213
  17. Kondapalli L, Hsia J, Miller R, Flaig TW, Bonaca MP. Burden of Cardiovascular Disease in?Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes. JACC CardioOncol. 2022 Dec; 4(5):649-656.
    View in: PubMed
    Score: 0.210
  18. Canonico ME, Hsia J, Cannon CP, Bonaca MP. Uptake of Newer Guideline-Directed Therapies in Heart?Failure Patients With Diabetes or Chronic Kidney Disease. JACC Heart Fail. 2022 12; 10(12):989-991.
    View in: PubMed
    Score: 0.208
  19. Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
    View in: PubMed
    Score: 0.203
  20. Hess CN, Szarek M, Anand SS, Bauersachs RM, Patel MR, Debus ES, Nehler MR, Capell WH, Beckman JA, Piazza G, Henkin S, Bura-Rivi?re A, Lawall H, Roztocil K, Hsia J, Muehlhofer E, Berkowitz SD, Haskell LP, Bonaca MP. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Netw Open. 2022 06 01; 5(6):e2215580.
    View in: PubMed
    Score: 0.202
  21. Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 06 07; 11(11):e025504.
    View in: PubMed
    Score: 0.202
  22. Hogan SE, Nehler MR, Anand S, Patel MR, Debus S, Jackson MT, Buchanan C, King RW, Hess C, Muehlhofer E, Haskell LP, Bauersachs RM, Berkowitz SD, Hsia J, Bonaca MP. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med. 2022 08; 27(4):343-349.
    View in: PubMed
    Score: 0.201
  23. Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 04; 246:136-143.
    View in: PubMed
    Score: 0.196
  24. Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, M?ty?s L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J. 2021 10 14; 42(39):4040-4048.
    View in: PubMed
    Score: 0.193
  25. Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, Capell WH, Hsia J, Beckman JA, Brodmann M, Diaz R, Habertheuer P, Leeper NJ, Powell RJ, Sillesen H, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation. 2021 12 07; 144(23):1831-1841.
    View in: PubMed
    Score: 0.193
  26. Morrison JT, Hsia J, Bonaca MP. Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. Heart Int. 2021; 15(1):14-19.
    View in: PubMed
    Score: 0.190
  27. Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
    View in: PubMed
    Score: 0.185
  28. Scimeca G, Krishnathasan D, Rashedi S, Lan Z, Sato A, Hamade N, Bejjani A, Khairani CD, Davies J, Porio N, Assi AA, Armero A, Tristani A, Ortiz-Rios MD, Nauffal V, Almarzooq Z, Wei E, Zuluaga-S?nchez V, Zarghami M, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Campia U, Bikdeli B, Piazza G. Predictors of venous thromboembolic events in hospitalized patients with COVID-19. J Thromb Thrombolysis. 2025 Apr; 58(4):485-496.
    View in: PubMed
    Score: 0.061
  29. Nurmohamed NS, van Rosendael AR, Danad I, Ngo-Metzger Q, Taub PR, Ray KK, Figtree G, Bonaca MP, Hsia J, Rodriguez F, Sandhu AT, Nieman K, Earls JP, Hoffmann U, Bax JJ, Min JK, Maron DJ, Bhatt DL. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. Eur Heart J. 2024 May 27; 45(20):1783-1800.
    View in: PubMed
    Score: 0.058
  30. Bikdeli B, Krishnathasan D, Khairani CD, Bejjani A, Davies J, Porio N, Tristani A, Armero A, Assi AA, Nauffal V, Campia U, Almarzooq Z, Wei E, Ortiz-Rios MD, Zuluaga-S?nchez V, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Grandone E, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Lan Z, Piazza G. Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19. Thromb Res. 2024 May; 237:209-215.
    View in: PubMed
    Score: 0.057
  31. Bikdeli B, Khairani CD, Krishnathasan D, Bejjani A, Armero A, Tristani A, Davies J, Porio N, Assi AA, Nauffal V, Campia U, Almarzooq Z, Wei E, Achanta A, Jesudasen SJ, Tiu BC, Merli GJ, Leiva O, Fanikos J, Sharma A, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll BJ, Lan Z, Goldhaber SZ, Piazza G. Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study. Thromb Res. 2023 08; 228:94-104.
    View in: PubMed
    Score: 0.054
  32. Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 06 20; 147(25):1891-1901.
    View in: PubMed
    Score: 0.054
  33. Canonico ME, Hsia J, Guthrie NL, Simmons M, Mehta P, Lupinacci P, Edwards K, Mosesso K, Gearhart M, Skuban A, Bonaca MP, Berman MA. Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial. Clin Cardiol. 2022 Aug; 45(8):850-856.
    View in: PubMed
    Score: 0.051
  34. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)